Rigel Pharmaceuticals (RIGL) Cash from Financing Activities (2010 - 2026)

Rigel Pharmaceuticals' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$10.9 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 2355.99% year-over-year to -$10.9 million in Q1 2026; TTM through Mar 2026 was -$10.8 million, a 24.95% decrease from a year earlier, with the FY2025 full-year figure at $601000.0, up 105.16% from the prior year.
• Cash from Financing Activities declined to -$10.9 million in Q1 2026 per RIGL's latest filing, from -$4.6 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $19.1 million in Q1 2023 and bottomed at -$10.9 million in Q1 2026.
• The 5-year median for Cash from Financing Activities is -$373000.0 (2023), against an average of $174000.0.
• Across the five-year window, Cash from Financing Activities jumped 1911.31% in 2022 and slumped 2355.99% in 2026, its largest moves.
• Year by year, Cash from Financing Activities stood at -$2.1 million in 2022, then soared by 123.19% to $486000.0 in 2023, then surged by 201.44% to $1.5 million in 2024, then tumbled by 412.08% to -$4.6 million in 2025, then plunged by 138.82% to -$10.9 million in 2026.
• Per Business Quant, the three latest RIGL Cash from Financing Activities figures stand at -$10.9 million (Q1 2026), -$4.6 million (Q4 2025), and $4.3 million (Q3 2025).